<DOC>
	<DOC>NCT01586195</DOC>
	<brief_summary>This is an open-label, multicenter, single-agent, phase II study of continuous oral Zelboraf (vemurafenib) in patients with locally-advanced, unresectable, stage IIIc or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.</brief_summary>
	<brief_title>Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Eastern Cooperative Oncology Group (ECOG) Performance Status 02 Histologicallyconfirmed metastatic melanoma (unresectable Stage IIIc or IV) with an activating BRAF mutation other than V600E Measurable disease (as defined by RECIST, v1.1) Adequate recovery from most recent systemic or local treatment for cancer Adequate organ function Women of childbearing potential and male partners of women of childbearing potential: agreement to use prescribed contraception. Negative serum pregnancy test within 7 days of commencement of treatment in premenopausal women. Women who are either surgically sterile or have been postmenopausal for at least 1 year are eligible to participate in this study Agreement not to donate blood or blood products during the study and for at least 6 months after discontinuation of vemurafenib; for male patients, agreement not to donate sperm during the study and for at least 6 months after discontinuation of vemurafenib Invasive malignancy other than melanoma at the time of enrollment and within 2 years prior Pregnant or breastfeeding Concurrent antitumor therapy (e.g., chemotherapy, other targeted therapy, radiation therapy, including participation in an experimental drug study) Either a concurrent condition or history of a prior condition that places the patient at unacceptable risk if he/she were treated with the study drug or confounds the ability to interpret data from the study Ongoing cardiac dysrhythmia &gt;/= Grade 2</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>